Biosimilar market on the growth path as top drugs double in size

Data shows while the overall biosimilars category has clocked a 10.3% value compound annual growth rate (CAGR) over the past few years, the market size for the top molecule has more than doubled

As the domestic market wakes up to a wider use of biologic drugs and as patient compliance improves, the biosimilars segment is seeing a higher growth of late. 

Data shows while the overall biosimilars category has clocked a 10.3 per cent value compound annual growth rate (CAGR) over the past few years, the market size for the top molecule has more than doubled. 

A biologic drug is produced from living organisms or contains components of living organisms, unlike chemical drugs. A biosimilar is a copy-cat of a biologic drug, once the patent period ends. The moving annual turover (MAT) for biosimilar molecules